

Franco Franceschini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8942223/publications.pdf>

Version: 2024-02-01

208
papers

6,775
citations

61984

43
h-index

74163

75
g-index

214
all docs

214
docs citations

214
times ranked

8576
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. <i>Autoimmunity Reviews</i> , 2020, 19, 102568.	5.8	637
2	Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. <i>Arthritis and Rheumatism</i> , 2001, 44, 1832-1835.	6.7	435
3	Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2328-2336.	0.7	214
4	Anti-Ro/SSA and La/SSB antibodies. <i>Autoimmunity</i> , 2005, 38, 55-63.	2.6	204
5	Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 2223-2231.	6.7	167
6	Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. <i>Lupus</i> , 2002, 11, 716-721.	1.6	140
7	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 584241.	4.8	137
8	Novel aspects of Sjögren's syndrome in 2012. <i>BMC Medicine</i> , 2013, 11, 93.	5.5	134
9	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
10	Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. <i>Blood Reviews</i> , 2021, 46, 100745.	5.7	129
11	Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. <i>Arthritis Research and Therapy</i> , 2012, 14, R97.	3.5	124
12	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1286-1289.	0.9	123
13	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
14	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2483-2498.	6.1	112
15	Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. <i>Journal of Immunological Methods</i> , 2016, 433, 1-5.	1.4	109
16	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 115-123.	3.4	107
17	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	5.8	105
18	COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. <i>Lancet Rheumatology</i> , The, 2020, 2, e549-e556.	3.9	105

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. <i>Clinical Rheumatology</i> , 2005, 24, 48-54.	2.2	101
20	Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. <i>British Journal of Rheumatology</i> , 2002, 41, 1357-1366.	2.3	98
21	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
22	Myositis autoantibodies and clinical phenotypes. <i>Autoimmunity Highlights</i> , 2014, 5, 69-75.	3.9	95
23	Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies. <i>Journal of Rheumatology</i> , 2011, 38, 1329-1334.	2.0	94
24	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	6.5	83
25	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
26	Systemic Sclerosis Therapy with Iloprost: A Prospective Observational Study of 30 Patients Treated for a Median of 3 Years. <i>Clinical Rheumatology</i> , 2002, 21, 244-250.	2.2	77
27	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. <i>Journal of Rheumatology</i> , 2020, 47, 377-386.	2.0	77
28	Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. <i>Lupus</i> , 2009, 18, 735-739.	1.6	68
29	Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 891-7.	0.8	66
30	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. <i>Autoimmunity Reviews</i> , 2015, 14, 692-702.	5.8	63
31	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
32	Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. <i>Lupus</i> , 2008, 17, 727-732.	1.6	58
33	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1905-1924.	6.1	58
34	Clinical Significance of IgA Anti-Cardiolipin and IgA Anti- β 2Glycoprotein I Antibodies. <i>Current Rheumatology Reports</i> , 2013, 15, 343.	4.7	53
35	Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. <i>Journal of Rheumatology</i> , 2002, 29, 1393-7.	2.0	53
36	Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma. <i>Journal of Rheumatology</i> , 2010, 37, 2071-2075.	2.0	52

#	ARTICLE	IF	CITATIONS
37	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Journal of Rheumatology</i> , 2017, 44, 1165-1172.	2.0	51
38	Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2008, 8, 104-106.	5.8	50
39	Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. <i>Lupus</i> , 2017, 26, 1197-1204.	1.6	50
40	Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. <i>Lupus</i> , 1999, 8, 215-219.	1.6	49
41	Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression. <i>Autoimmunity Reviews</i> , 2009, 8, 580-584.	5.8	46
42	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	5.8	46
43	Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. <i>Lupus</i> , 2003, 12, 735-740.	1.6	45
44	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. <i>Journal of Rheumatology</i> , 2009, 36, 1464-1469.	2.0	45
45	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2017, 36, 469-475.	2.2	45
46	The 2016 classification criteria for primary Sjogren's syndrome: what's new?. <i>BMC Medicine</i> , 2017, 15, 69.	5.5	43
47	Prevalence, Clinical, and Laboratory Features of Thrombocytopenia Among HIV-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 261-269.	1.1	41
48	Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. <i>Arthritis and Rheumatism</i> , 2011, 63, 1972-1978.	6.7	40
49	The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1365-1368.	1.6	40
50	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 11.	2.4	39
51	Cardiological features in idiopathic inflammatory myopathies. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 906-911.	1.5	38
52	Deforming Arthropathy of the Hands in Systemic Lupus Erythematosus is Associated with Antibodies to SSA/Ro and to SSB/La. <i>Lupus</i> , 1994, 3, 419-422.	1.6	35
53	Rare autoantibodies to cellular antigens in systemic lupus erythematosus. <i>Lupus</i> , 2014, 23, 672-677.	1.6	35
54	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34

#	ARTICLE	IF	CITATIONS
55	Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 2180-2185.	2.0	33
56	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. <i>Autoimmunity</i> , 2013, 46, 363-368.	2.6	33
57	DNA typing of maternal HLA in congenital complete heart block: Comparison with systemic lupus erythematosus and primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1999, 42, 1757-1764.	6.7	32
58	Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients. <i>Rheumatology</i> , 2016, 55, 315-319.	1.9	32
59	Anti-RNA Polymerase III Antibodies as a Risk Marker for Early Gastric Antral Vascular Ectasia (GAVE) in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 1544.1-1544.	2.0	31
60	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
61	Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays. <i>Journal of Autoimmunity</i> , 2002, 19, 71-77.	6.5	29
62	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	3.8	28
63	Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures. <i>Immunologic Research</i> , 2017, 65, 150-156.	2.9	27
64	Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship. <i>Current Rheumatology Reviews</i> , 2019, 15, 177-188.	0.8	27
65	The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 88-98.	6.5	26
66	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1764-1769.	2.3	25
67	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020, 59, 2272-2281.	1.9	25
68	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	6.5	25
69	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021, 8, 614829.	2.6	25
70	Antiphospholipid antibodies mediate autoimmunity against dying cells. <i>Autoimmunity</i> , 2013, 46, 302-306.	2.6	24
71	Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 87-94.	6.5	24
72	Association Between Changes in BlyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab. <i>Frontiers in Pharmacology</i> , 2019, 10, 433.	3.5	23

#	ARTICLE	IF	CITATIONS
73	Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 412-430.	6.5	23
74	Update on Antiphospholipid Syndrome: Ten Topics in 2017. <i>Current Rheumatology Reports</i> , 2018, 20, 15.	4.7	22
75	Transient neonatal bradycardia without heart block associated with anti-Ro antibodies. <i>Lupus</i> , 1997, 6, 487-488.	1.6	21
76	Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events. <i>Arthritis Care and Research</i> , 2018, 70, 1277-1283.	3.4	21
77	The clinico-serological spectrum of overlap myositis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 637-643.	4.3	20
78	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 540.	2.4	20
79	Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. <i>Israel Medical Association Journal</i> , 2014, 16, 651-3.	0.1	20
80	Hepatitis C virus infection and primary Sjögren's Syndrome: A clinical and serologic description of 9 patients. <i>Autoimmunity Reviews</i> , 2008, 8, 92-94.	5.8	19
81	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012, 14, R2.	3.5	19
82	Macrophage activation syndrome in adult systemic lupus erythematosus: report of seven adult cases from a single Italian rheumatology center. <i>Reumatismo</i> , 2018, 70, 100-105.	0.9	19
83	C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. <i>NeuroMolecular Medicine</i> , 2019, 21, 150-159.	3.4	19
84	A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. <i>Rheumatology</i> , 2020, 59, 2412-2418.	1.9	19
85	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg's Syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	6.7	19
86	Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?. <i>Reumatismo</i> , 2012, 64, 321-5.	0.9	18
87	Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. <i>Journal of Immunological Methods</i> , 2019, 474, 112661.	1.4	18
88	Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. <i>Rheumatology</i> , 2020, 59, 1769-1770.	1.9	18
89	Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors. <i>Lupus</i> , 2019, 28, 210-216.	1.6	17
90	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicines</i> , 2021, 9, 671.	3.2	17

#	ARTICLE	IF	CITATIONS
91	Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 303-308.	0.8	16
92	Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). <i>Autoimmunity</i> , 2011, 44, 90-97.	2.6	15
93	Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. <i>Lupus</i> , 2014, 23, 1255-1258.	1.6	15
94	Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety. <i>Journal of Rheumatology</i> , 2015, 42, 193-195.	2.0	15
95	Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa017.	0.7	15
96	The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus. <i>Reumatismo</i> , 2016, 68, 137-143.	0.9	14
97	Novel Therapies in Takayasu Arteritis. <i>Frontiers in Medicine</i> , 2021, 8, 814075.	2.6	14
98	Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis. <i>Journal of Investigative Medicine</i> , 2012, 60, 1204-1208.	1.6	13
99	Left ventricular function in rheumatoid arthritis during anti-TNF- α treatment: a speckle tracking prospective echocardiographic study. <i>Monaldi Archives for Chest Disease</i> , 2016, 84, 716.	0.6	13
100	Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?. <i>Journal of Neuroimmunology</i> , 2018, 325, 61-63.	2.3	13
101	Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. <i>Rheumatology</i> , 2021, 60, 2916-2926.	1.9	13
102	Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases. <i>Frontiers in Medicine</i> , 2022, 9, 849086.	2.6	13
103	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
104	Chilblain Lupus Erythematosus is Associated with Antibodies to SSA/Ro. <i>Advances in Experimental Medicine and Biology</i> , 1999, 455, 167-171.	1.6	12
105	Antinuclear antibodies are not induced by PUVA treatment in patients with uncomplicated psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 955-958.	1.2	11
106	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 572876.	4.8	11
107	The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhuri Cure M et al.. <i>Clinical Rheumatology</i> , 2020, 39, 2489-2490.	2.2	11
108	Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, , 1.	6.5	11

#	ARTICLE	IF	CITATIONS
109	Clinical and serological features of 35 patients with anti-Ki autoantibodies. <i>Lupus</i> , 2005, 14, 837-841.	1.6	10
110	Complement Cascade in Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 427-434.	3.8	10
111	Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-“Tumor Necrosis Factor” Therapy. <i>Clinical Cardiology</i> , 2014, 37, 738-743.	1.8	10
112	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , 2017, 56, 1874-1883.	1.9	10
113	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , 2019, 58, 2000-2008.	1.9	10
114	Winter lupus flares are associated with low vitamin D levels in a retrospective longitudinal study of Italian adult patients. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 153-8.	0.8	10
115	CD4+ and CD8+ subsets: Naive and memory cells in the peripheral blood of patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 1994, 13, 83-87.	2.2	9
116	In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. <i>European Journal of Dermatology</i> , 2014, 24, 349-355.	0.6	9
117	Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 81-91.	1.9	9
118	Response to: “Correspondence on “Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome”” by Kawada. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e78-e78.	0.9	9
119	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 3176-3188.	1.9	9
120	Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?. <i>European Journal of Internal Medicine</i> , 2020, 73, 76-82.	2.2	8
121	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 1) Tj ETQq1 1 0,784314 rgBT /Over	1.9	8
122	Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience. <i>Bioanalysis</i> , 2020, 12, 1223-1230.	1.5	8
123	Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e152-e152.	0.9	8
124	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 358-377.	6.5	8
125	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 19-26.	0.8	8
126	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 91-97.	0.8	8

#	ARTICLE	IF	CITATIONS
127	Elastic properties of the ascending aorta in patients with rheumatoid arthritis. <i>International Journal of Cardiology</i> , 2011, 150, 368-369.	1.7	7
128	Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. <i>Arthritis Care and Research</i> , 2018, 70, 1218-1227.	3.4	7
129	Autoantibodies™ titre modulation by anti-BlyS treatment in systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 1074-1081.	1.6	7
130	Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. <i>Arthritis Care and Research</i> , 2021, 73, 1804-1808.	3.4	7
131	Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis. <i>Frontiers in Medicine</i> , 2021, 8, 754434.	2.6	7
132	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
133	Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. <i>Clinical Rheumatology</i> , 2019, 38, 609-610.	2.2	6
134	Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic. <i>Clinical Rheumatology</i> , 2021, 40, 239-244.	2.2	6
135	Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study. <i>Autoimmunity Reviews</i> , 2021, 20, 102757.	5.8	6
136	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3020-3023.	6.1	6
137	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 240-250.	6.5	6
138	Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 321-342.	6.5	6
139	A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 118-21.	0.8	6
140	Absence of a correlation between T lymphocyte subsets and clinical activity in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1989, 22, 41-45.	2.3	5
141	Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 29-33.	1.0	5
142	Pathogenetic associations of maternal Anti-Ro/SSA antibodies. <i>Lupus</i> , 2002, 11, 650-650.	1.6	5
143	The Influence of Treatment of Inflammatory Arthritis During Pregnancy on the Long-Term Children™s Outcome. <i>Frontiers in Pharmacology</i> , 2021, 12, 626258.	3.5	5
144	Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 666971.	3.5	5

#	ARTICLE	IF	CITATIONS
145	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 93-102.	0.8	5
146	Antiperinuclear factor in psoriatic arthropathy. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 910-913.	1.2	4
147	Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide. <i>Joint Bone Spine</i> , 2015, 82, 130-131.	1.6	4
148	Diastolic dysfunction in rheumatoid arthritis: a usual travel-mate?. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	4
149	Long-term outcome for the mothers of infants with isolated congenital complete heart block: Comment on the article by Julkunen et al. <i>Arthritis and Rheumatism</i> , 1994, 37, 1261-1261.	6.7	3
150	Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies. <i>Lupus</i> , 2017, 26, 1121-1122.	1.6	3
151	Impact of COVID-19 on outpatient therapy with iloprost for systemic sclerosis digital ulcers. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 109-110.	1.7	3
152	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. <i>Lupus</i> , 2021, 30, 1233-1243.	1.6	3
153	Neuropsychiatric Outcome of Children Born to Women With Systemic Lupus Erythematosus and Exposed in Utero to Azathioprine: A Case-Control Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 613239.	3.5	3
154	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 25-28.	0.8	3
155	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	3
156	Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 2852-2853.	6.7	2
157	Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 523-536.	2.4	2
158	FRI0480â€¦SCHNITZLERâ€™S SYNDROME: DESCRIPTION OF AN ITALIAN MULTICENTER COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 837.1-837.	0.9	2
159	Autoimmune Polyendocrine Syndromes. , 2008, , 265-269.		2
160	Antibodies against antigens related to scleroderma in a cohort of patients with morphea. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 451-458.	0.2	2
161	Women of childbearing age living with spondyloarthritis: time for improving knowledge and counselling about reproductive issues. <i>Rheumatology</i> , 2022, 61, 1307-1309.	1.9	2
162	Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 352.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Anti-MJ/NXP-2 antibodies are the most common specificity in a cohort of adult caucasian patients with dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A49.2-A49.	0.9	1
164	Centromere Autoantibodies. , 2014, , 179-183.		1
165	Treatment and functional outcome of patients with cystoid macular edema: a single-center experience. <i>Clinical Rheumatology</i> , 2015, 34, 791-794.	2.2	1
166	AB0668â€¦ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY AND BREAST IMPLANTS RUPTURE IN ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		1
167	FRI0387â€¦DISEASE COURSE AND OUTCOMES DURING PREGNANCY IN PATIENTS WITH AXIAL SPONDILOARTHRITIS: COMPARISON BETWEEN TNFI USERS AND NAIVE PATIENTS. , 2019, , .		1
168	FRI0217â€¦SENSITIVITY AND SPECIFICITY OF 2019 DCVAS DRAFT CLASSIFICATION CRITERIA FOR GIANT CELLS ARTERITIS AND TAKAYASU ARTERITIS IN A MONOCENTRIC COHORT OF PATIENTS WITH CLINICAL DIAGNOSIS OF LARGE VESSEL VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 692.2-692.	0.9	1
169	FRI0105â€¦EVALUATION OF CXCL13 AND ICAM1 SERUM LEVELS AS PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN RHEUMATOID ARTHRITIS.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 632.2-632.	0.9	1
170	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 91-97.	0.8	1
171	CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
172	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695-695.	0.8	1
173	Rheumatoid arthritis and diabetes mellitus: Two faces of one coin? Comment on the article by Peters et al. <i>Arthritis Care and Research</i> , 2010, 62, 1201-1202.	3.4	0
174	Dr. Reggia, <i>et al,</i> reply. <i>Journal of Rheumatology</i> , 2015, 42, 1995.1-1995.	2.0	0
175	Atteinte cutanÃ©e sÃ©vÃ©re au cours d'une cryoglobulinÃ©mie de type II traitÃ©e efficacement par le thalidomide. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 208-209.	0.0	0
176	FRI0235â€¦DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER EXPERIENCE OVER 20 YEARS OF FOLLOW-UP. , 2019, , .		0
177	AB0481â€¦AUTOANTIBODIESâ€™ TITRE MODULATION BY ANTI-BLYS TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
178	FRI0207â€¦BASELINE LEVELS OF BAFF, APRIL AND CD8+ EFFECTOR MEMORY CELLS AS PREDICTORS OF SLEDAI RESPONSE TO BELIMUMAB THERAPY. , 2019, , .		0
179	FRI0330â€¦MALIGNANCIES IN SYSTEMIC SCLEROSIS PATIENTSWITH ANTI-PM/SCL ANTIBODIES: AN EUSTAR CASE-CONTROL STUDY. , 2019, , .		0
180	THU0519â€¦DISEASE COURSE AND OUTCOMES OF PREGNANCY IN JUVENIL IDIOPHATIC ARTHRITIS: ANY DIFFERENCE AMONG DISEASE SUBSETS?. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
181	AB0512â€¦ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: ARE THEY USEFUL?. , 2019, , .		0
182	AB0955â€¦TRANSITIONAL CARE: A SINGLE CENTER ITALIAN EXPERIENCE. , 2019, , .		0
183	P74â€¦Complement variations in systemic lupus erythematosus pregnancies. , 2020, , .		0
184	P75â€¦Anti-SSA/Ro positivity and the risk of congenital heart block: obstetric and fetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases. , 2020, , .		0
185	P136â€¦SLEDAI response prediction to belimumab therapy by baseline levels of BlyS, APRIL and CD8+ effector memory T-cells. , 2020, , .		0
186	P15â€¦Anti-carbamylated protein antibodiesâ€™ levels are negatively correlated with circulating effector T-cells in a cohort of patients with systemic lupus erythematosus. , 2020, , .		0
187	P22â€¦Anti-carbamylated protein antibodies in systemic lupus erythematosus: clinical and serological associations. , 2020, , .		0
188	P54â€¦Incidence of skin cancer in systemic lupus erythematosus compared with systemic sclerosis and general population. , 2020, , .		0
189	Maternal, pregnancy and neonatal outcomes of twin gestations in women with rheumatic diseases: A single-center, case-control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 264, 49-55.	1.1	0
190	FRI0239â€¦ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY. Annals of the Rheumatic Diseases, 2020, 79, 703.1-704.	0.9	0
191	AB0523â€¦TAKAYASU ARTERITIS AND SACROILIITIS: A CASE-CONTROL STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1559.2-1559.	0.9	0
192	AB0678â€¦RISK FACTORS FOR ADVERSE PREGNANCY OUTCOMES IN SPONDYLOARTHRITIS: DISEASE PHENOTYPE AND DISEASE ACTIVITY MAY PLAY A ROLE. Annals of the Rheumatic Diseases, 2020, 79, 1634.1-1634.	0.9	0
193	THU0344â€¦CLINICAL AND HISTOLOGICAL SPECTRUM OF ANTI-MI2 DERMATOMYOSITIS: A MULTICENTRE RETROSPECTIVE COHORT. Annals of the Rheumatic Diseases, 2020, 79, 403-403.	0.9	0
194	SAT0207â€¦ANTI-SSA/RO POSITIVITY AND CONGENITAL HEART BLOCK: OBSTETRIC AND FETAL OUTCOME IN A COHORT OF ANTI-SSA/RO POSITIVE PREGNANT WOMEN WITH AND WITHOUT AUTO-IMMUNE DISEASES FROM THREE ITALIAN TERTIARY REFERRAL CENTERS. Annals of the Rheumatic Diseases, 2020, 79, 1046.1-1047.	0.9	0
195	AB0423â€¦NEUROPSYCHIATRIC OUTCOME OF CHILDREN BORN TO WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WOMEN AND EXPOSED IN UTERO TO AZATHIOPRINE: A CASE-CONTROL STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 1511.2-1511.	0.9	0
196	AB0624â€¦PREDICTIVE PARAMETERS FOR DEVELOPMENT OF INTERSTITIAL LUNG DISEASE IN IDIOPATHIC INFLAMMATORY MYOSITIS. Annals of the Rheumatic Diseases, 2020, 79, 1607.2-1607.	0.9	0
197	SAT0202â€¦C4 LEVELS AS PREDICTOR OF DISEASE FLARES AND ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES. Annals of the Rheumatic Diseases, 2020, 79, 1043.2-1043.	0.9	0
198	AB0623â€¦RATE AND PREDICTIVE FACTORS ASSOCIATED WITH SUSTAINED REMISSION IN IDIOPATHIC INFLAMMATORY MYOSITIS. Annals of the Rheumatic Diseases, 2020, 79, 1607.1-1607.	0.9	0

#	ARTICLE	IF	CITATIONS
199	SAT0368â€¦PREGNANCY IN WOMEN WITH SPONDYLOARTHRITIS: WHO ARE THE PATIENTS AT RISK OF DISEASE FLARE?. Annals of the Rheumatic Diseases, 2020, 79, 1131-1132.	0.9	0
200	AB0522â€¦GENDER DIFFERENCES IN GIANT CELLS ARTERITIS: ANALYSIS OF A MONOCENTRIC COHORT OF 100 PATIENTS.. Annals of the Rheumatic Diseases, 2020, 79, 1558.2-1559.	0.9	0
201	AB0681â€¦COMPARISON BETWEEN DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PREDOMINANT AXIAL VS MAINLY PERIPHERAL SPONDYLOARTHRITIS (SpA) PATIENTS, ENROLLED IN THE ONGOING SIRENA STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1636.1-1636.	0.9	0
202	SAT0328â€¦OUTCOME OF INTERSTITIAL LUNG DISEASE (ILD) IN ANTI-PM/SCL PATIENTS WITH SYSTEMIC SCLEROSIS: RESULTS FROM AN EUSTAR CASE-CONTROL STUDY.. Annals of the Rheumatic Diseases, 2020, 79, 1109.2-1110.	0.9	0
203	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695.	0.8	0
204	Reply to: Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis by Castellanos-Moreira et al. Clinical and Experimental Rheumatology, 2021, 39, 1144.	0.8	0
205	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). Thrombosis and Haemostasis, 2022, 122, 1612-1620.	3.4	0
206	CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
207	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
208	Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0